Floatz logo

ABATACEPT RECOMBINANT

Primary Biliary Cholangitis

Eli Lilly and Companyprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Primary Biliary Cholangitis cohort.

Asset / SponsorPhaseRating
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
Mbx-8025
Gilead Sciences
Phase 3BB
cs0159
Cascade Pharmaceuticals, Inc
Phase 3BB
Obeticholic Acid
Intercept Pharmaceuticals
Phase 3BB
2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID
Intercept Pharmaceuticals
Phase 3BB

View all 33 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →
acute biphenotypic leukemiaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →